Abstract:To determine whether pro-inflammatory lipid lysophosphatidylinositols (LPIs) upregulate the expressions of membrane proteins for adhesion/signaling and secretory proteins in human aortic endothelial cell (HAEC) activation, we developed an EC biology knowledge-based transcriptomic formula to profile RNA-Seq data panoramically. We made the following primary findings: first, G protein-coupled receptor 55 (GPR55), the LPI receptor, is expressed in the endothelium of both human and mouse aortas, and is significantly upregulated in hyperlipidemia; second, LPIs upregulate 43 clusters of differentiation (CD) in HAECs, promoting EC activation, innate immune trans-differentiation, and immune/inflammatory responses; 72.1% of LPI-upregulated CDs are not induced in influenza virus-, MERS-CoV virus- and herpes virus-infected human endothelial cells, which hinted the specificity of LPIs in HAEC activation; third, LPIs upregulate six types of 640 secretomic genes (SGs), namely, 216 canonical SGs, 60 caspase-1-gasdermin D (GSDMD) SGs, 117 caspase-4/11-GSDMD SGs, 40 exosome SGs, 179 Human Protein Atlas (HPA)-cytokines, and 28 HPA-chemokines, which make HAECs a large secretory organ for inflammation/immune responses and other functions; fourth, LPIs activate transcriptomic remodeling by upregulating 172 transcription factors (TFs), namely, pro-inflammatory factors NR4A3, FOS, KLF3, and HIF1A; fifth, LPIs upregulate 152 nuclear DNA-encoded mitochondrial (mitoCarta) genes, which alter mitochondrial mechanisms and functions, such as mitochondrial organization, respiration, translation, and transport; sixth, LPIs activate reactive oxygen species (ROS) mechanism by upregulating 18 ROS regulators; finally, utilizing the Cytoscape software, we found that three mechanisms, namely, LPI-upregulated TFs, mitoCarta genes, and ROS regulators, are integrated to promote HAEC activation. Our results provide novel insights into aortic EC activation, formulate an EC biology knowledge-based transcriptomic profile strategy, and identify new targets for the development of therapeutics for cardiovascular diseases, inflammatory conditions, immune diseases, organ transplantation, aging, and cancers.

Lysophospholipid Receptors, As Novel Conditional Danger Receptors and Homeostatic Receptors Modulate Inflammation-Novel Paradigm and Therapeutic Potential

Lysophospholipids and Their Receptors Serve As Conditional DAMPs and DAMP Receptors in Tissue Oxidative and Inflammatory Injury.

NMI and IFP35 serve as proinflammatory DAMPs during cellular infection and injury

Lysophospholipids Induce Innate Immune Transdifferentiation of Endothelial Cells, Resulting in Prolonged Endothelial Activation

Plasmalogenic Lipid Analogs as Platelet-Activating Factor Antagonists: A Potential Novel Class of Anti-inflammatory Compounds

Metabolism-Associated Molecular Patterns (MAMPs)

Metabolite-derived Damage-Associated Molecular Patterns in Immunological Diseases.

Old and New Damage‐associated Molecular Patterns (damps) in Autoimmune Diseases

Increased Acetylation of H3K14 in the Genomic Regions That Encode Trained Immunity Enzymes in Lysophosphatidylcholine-Activated Human Aortic Endothelial Cells – Novel Qualification Markers for Chronic Disease Risk Factors and Conditional DAMPs

DAMP sensing and sterile inflammation: intracellular, intercellular and inter-organ pathways

Integrative Proteomic Analysis of Multiple Posttranslational Modifications in Inflammatory Response

DAMP-sensing Receptors in Sterile Inflammation and Inflammatory Diseases

Endogenous Pro-Resolving and Anti-Inflammatory Lipid Mediators: the New Hope of Atherosclerotic Diseases.

Lipid Mediators in Health and Disease: Enzymes and Receptors as Therapeutic Targets for the Regulation of Immunity and Inflammation

DAMPs and DAMP-sensing receptors in inflammation and diseases

Dual Functioned Hexapeptide-Coated Lipid-Core Nanomicelles Suppress Toll-Like Receptor-Mediated Inflammatory Responses through Endotoxin Scavenging and Endosomal pH Modulation

Recent Advances in Anti-Inflammation Via AMPK Activation

Lysophospholipid Metabolism Facilitates Toll-like Receptor 4 Membrane Translocation to Regulate the Inflammatory Response

Bidirectional crosstalk of the cAMP/ROS-dependent signaling pathways in inflammatory macrophage: An activation of formononetin

Identification and characterization of a novel adiponectin receptor agonist adipo anti‐inflammation agonist and its anti‐inflammatory effects in vitro and in vivo

Novel Knowledge-Based Transcriptomic Profiling of Lipid Lysophosphatidylinositol-Induced Endothelial Cell Activation